Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Kidney Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
5 drugs · 8 active trials
17 drugs · 284 active trials
Data updated 17 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Nivolumab | Approved | Phase 4 | 59 | 26 | 17 | 126 | 3 | US | Dec 22, 2014 | May 31, 2011 |
| Pembrolizumab | Approved | Phase 3 | 51 | 23 | 13 | 112 | 2 | US | Sep 4, 2014 | Nov 15, 2013 |
| Cabozantinib | Approved | Phase 4 | 42 | 20 | 13 | 65 | 3 | EU, US | Apr 25, 2016 | 2010-04 |
| Ipilimumab | Approved | Phase 4 | 35 | 20 | 8 | 60 | 1 | US | Mar 25, 2011 | 2003-02 |
| Axitinib | Approved | Phase 3 | 22 | 10 | 5 | 53 | 4 | EU, US | Jan 27, 2012 | Dec 12, 2007 |
| Belzutifan | Approved | Phase 3 | 19 | 7 | 7 | 24 | 2 | US | Aug 13, 2021 | Dec 7, 2016 |
| Lenvatinib | Approved | Phase 4 | 16 | 6 | 6 | 31 | 3 | EU, US | Feb 13, 2015 | Aug 5, 2010 |
| Sunitinib | Approved | Phase 4 | 10 | 1 | 18 | 116 | 1 | US | Jan 26, 2006 | 2004-02 |
| Bevacizumab | Approved | Phase 3 | 7 | 3 | 8 | 64 | 1 | US | Feb 26, 2004 | 1998-11 |
| Everolimus | Approved | Phase 4 | 5 | 0 | 7 | 62 | 3 | EU, US | Mar 30, 2009 | 2004-12 |
| Pazopanib | Approved | Phase 4 | 5 | 2 | 8 | 54 | 1 | US | Oct 19, 2009 | Sep 28, 2004 |
| Avelumab | Approved | Phase 3 | 5 | 1 | 3 | 15 | 1 | US | Mar 23, 2017 | Oct 26, 2015 |
| Aldesleukin | Approved | Phase 4 | 4 | 2 | 8 | 51 | 1 | US | May 5, 1992 | 1991-04 |
| Tivozanib | Approved | Phase 3 | 3 | 2 | 5 | 13 | 2 | EU, US | Aug 24, 2017 | 2007-10 |
| Sorafenib | Approved | Phase 3 | 1 | 1 | 11 | 42 | 1 | US | Dec 1, 2005 | 2002-09 |
| Temsirolimus | Approved | Phase 3 | 0 | 0 | 3 | 24 | 1 | US | May 30, 2007 | 2002-04 |
| Sorafenib Tosylate | Approved | Phase 3 | 0 | 0 | 2 | 14 | 1 | US | Dec 1, 2005 | 2004-09 |
| Palbociclib | Phase 4 | Phase 4 | 3 | 1 | 0 | 7 | 0 | — | — | Aug 17, 2015 |
| Olaparib | Phase 4 | Phase 4 | 3 | 2 | 0 | 5 | 0 | — | — | Jun 26, 2015 |
| Erlotinib | Phase 4 | Phase 4 | 1 | 1 | 0 | 7 | 0 | — | — | 2004-06 |
| Immune Checkpoint Inhibitor | Phase 4 | Phase 4 | 1 | 1 | 0 | 1 | 0 | — | — | Jun 8, 2026 |
| Zoledronic Acid | Phase 4 | Phase 4 | 0 | 0 | 0 | 4 | 0 | — | — | 2003-08 |
| Atezolizumab | Phase 3 | Phase 3 | 12 | 4 | 5 | 25 | 0 | — | — | 2016-11 |
| Cyclophosphamide | Phase 3 | Phase 3 | 8 | 7 | 6 | 46 | 0 | — | — | 1990-05 |
| Durvalumab | Phase 3 | Phase 3 | 6 | 1 | 3 | 15 | 0 | — | — | Dec 19, 2013 |
| Carboplatin | Phase 3 | Phase 3 | 5 | 4 | 3 | 17 | 0 | — | — | 1992-10 |
| Doxorubicin | Phase 3 | Phase 3 | 3 | 3 | 9 | 19 | 0 | — | — | 1990-05 |
| Irinotecan | Phase 3 | Phase 3 | 3 | 2 | 1 | 9 | 0 | — | — | 1999-08 |
| Ipilimumab/Nivolumab Regimen | Phase 3 | Phase 3 | 3 | 0 | 1 | 8 | 0 | — | — | 2016-10 |
| Gemcitabine | Phase 3 | Phase 3 | 2 | 1 | 1 | 27 | 0 | — | — | 1998-10 |
| Etoposide | Phase 3 | Phase 3 | 2 | 2 | 5 | 13 | 0 | — | — | 1990-05 |
| Fluorouracil | Phase 3 | Phase 3 | 2 | 0 | 2 | 11 | 0 | — | — | 1996-08 |
| Vincristine | Phase 3 | Phase 3 | 2 | 2 | 7 | 11 | 0 | — | — | 1990-05 |
| Cisplatin | Phase 3 | Phase 3 | 2 | 1 | 1 | 9 | 0 | — | — | 1999-01 |
| Tremelimumab | Phase 3 | Phase 3 | 2 | 1 | 1 | 8 | 0 | — | — | 2006-11 |
| Savolitinib | Phase 3 | Phase 3 | 2 | 0 | 2 | 5 | 0 | — | — | Apr 30, 2014 |
| Prednisone | Phase 3 | Phase 3 | 2 | 1 | 1 | 3 | 0 | — | — | 1998-07 |
| Dactinomycin | Phase 3 | Phase 3 | 1 | 1 | 8 | 10 | 0 | — | — | 1993-07 |
| Ifosfamide | Phase 3 | Phase 3 | 1 | 1 | 2 | 8 | 0 | — | — | 1990-05 |
| Enzalutamide | Phase 3 | Phase 3 | 1 | 0 | 1 | 4 | 0 | — | — | Feb 11, 2015 |
| Chemotherapy | Phase 3 | Phase 3 | 1 | 0 | 1 | 3 | 0 | — | — | 1996-03 |
| Abexinostat | Phase 3 | Phase 3 | 1 | 1 | 1 | 1 | 0 | — | — | Jul 17, 2018 |
| Abiraterone | Phase 3 | Phase 3 | 1 | 0 | 1 | 1 | 0 | — | — | Jul 30, 2026 |
| Alectinib | Phase 3 | Phase 3 | 1 | 1 | 1 | 1 | 0 | — | — | Dec 18, 2023 |
| Fruquintinib | Phase 3 | Phase 3 | 1 | 0 | 1 | 1 | 0 | — | — | Oct 27, 2022 |
| Filgrastim | Phase 3 | Phase 3 | 0 | 0 | 4 | 17 | 0 | — | — | 1992-10 |
| Thalidomide | Phase 3 | Phase 3 | 0 | 0 | 1 | 5 | 0 | — | — | 1998-11 |
| Denosumab | Phase 3 | Phase 3 | 0 | 0 | 1 | 3 | 0 | — | — | Nov 16, 2009 |
| Dovitinib | Phase 3 | Phase 3 | 0 | 0 | 1 | 2 | 0 | — | — | 2011-03 |
| Peginterferon Alfa-2a | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | 2004-01 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.